NextCell Pharma AB (NXTCL.ST)
SEK 0.96
(9.17%)
SEK 0.96
(9.17%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 545.23 Thousand SEK | -31.04% |
| 2023 | 790.66 Thousand SEK | 3.09% |
| 2022 | 766.96 Thousand SEK | 76696800.0% |
| 2021 | 1.00 SEK | 0.0% |
| 2020 | 1.00 SEK | 100.0% |
| 2019 | -2.7 Million SEK | -40.58% |
| 2018 | -1.92 Million SEK | -192668100.0% |
| 2017 | 1.00 SEK | 100.0% |
| 2016 | -592.15 Thousand SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q4 | 545.23 Thousand SEK | -31.04% |
| 2024 Q3 | 790.66 Thousand SEK | 0.0% |
| 2024 Q2 | 790.66 Thousand SEK | 0.0% |
| 2024 Q1 | 790.66 Thousand SEK | 0.0% |
| 2023 Q3 | 766.96 Thousand SEK | 0.0% |
| 2023 Q2 | 766.96 Thousand SEK | 0.0% |
| 2023 FY | 790.66 Thousand SEK | 3.09% |
| 2023 Q4 | 790.66 Thousand SEK | 3.09% |
| 2023 Q1 | 766.96 Thousand SEK | 0.0% |
| 2022 Q1 | 6.55 Million SEK | 571.12% |
| 2022 Q2 | -3.69 Million SEK | -156.46% |
| 2022 Q3 | 11.07 Million SEK | 399.5% |
| 2022 Q4 | 766.96 Thousand SEK | -93.08% |
| 2022 FY | 766.96 Thousand SEK | 76696800.0% |
| 2021 Q1 | 3.18 Million SEK | -2.17% |
| 2021 FY | 1.00 SEK | 0.0% |
| 2021 Q4 | -1.39 Million SEK | 73.71% |
| 2021 Q3 | -5.28 Million SEK | -528947400.0% |
| 2021 Q2 | 1.00 SEK | -100.0% |
| 2020 Q1 | 1.00 SEK | 100.0% |
| 2020 FY | 1.00 SEK | 100.0% |
| 2020 Q4 | 3.25 Million SEK | 325279300.0% |
| 2020 Q3 | 1.00 SEK | 100.0% |
| 2020 Q2 | -971.08 Thousand SEK | -97108600.0% |
| 2019 Q2 | 1.00 SEK | 100.0% |
| 2019 FY | -2.7 Million SEK | -40.58% |
| 2019 Q4 | -360.03 Thousand SEK | -15.82% |
| 2019 Q3 | -310.85 Thousand SEK | -31085200.0% |
| 2019 Q1 | -45.33 Thousand SEK | 19.89% |
| 2018 Q4 | -56.59 Thousand SEK | -105.6% |
| 2018 FY | -1.92 Million SEK | -192668100.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q3 | 1.01 Million SEK | 101066500.0% |
| 2018 Q2 | 1.00 SEK | 0.0% |
| 2017 Q2 | 1.00 SEK | 0.0% |
| 2017 FY | 1.00 SEK | 100.0% |
| 2017 Q1 | - SEK | 100.0% |
| 2017 Q3 | -88.7 Thousand SEK | -8870100.0% |
| 2017 Q4 | 1.00 SEK | 100.0% |
| 2016 FY | -592.15 Thousand SEK | 0.0% |
| 2016 Q4 | -157.6 Thousand SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 221.981% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 99.49% |
| AcouSort AB (publ) | 2.08 Million SEK | 73.787% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 163.179% |
| Xintela AB (publ) | 398 Thousand SEK | -36.994% |
| Ziccum AB (publ) | -4.18 Million SEK | 113.016% |
| Active Biotech AB (publ) | -2500.00 SEK | 21909.48% |
| Alzinova AB (publ) | -3.27 Million SEK | 116.633% |
| Amniotics AB (publ) | 534 Thousand SEK | -2.104% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -27261750.0% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 97.331% |
| Camurus AB (publ) | 100.95 Million SEK | 99.46% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 86.484% |
| CombiGene AB (publ) | -1.79 Million SEK | 130.308% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 97.733% |
| Genovis AB (publ.) | 14.9 Million SEK | 96.342% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 36791.588% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 28060.872% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 133.532% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 98.452% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 1.00 SEK | -54523600.0% |
| Simris Alg AB (publ) | 1.09 Million SEK | 50.024% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 98.755% |
| Intervacc AB (publ) | 10.48 Million SEK | 94.799% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 107.641% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 114.136% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -54423.7% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 93.987% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 82.691% |
| Biovica International AB (publ) | 2.19 Million SEK | 75.205% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -54523600.0% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 22.109% |
| 2cureX AB (publ) | -1000.00 SEK | 54623.7% |
| I-Tech AB | 4.28 Million SEK | 87.261% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 94.432% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 111.062% |
| Nanologica AB (publ) | 2.97 Million SEK | 81.66% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 95.397% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 269.779% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 77.516% |
| Pila Pharma AB (publ) | 1.00 SEK | -54523600.0% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 46.961% |